)To keep you up-to-date on the latest scientific findings and on the clinical management of CML the iCMLf is pleased to present to you monthly updates from key CML publications in peer-reviewed journals.

The iCMLf 'Publications of the month' are brought to you by Professor Timothy Hughes. From the many papers on CML published this month Professor Hughes has selected topical, interesting papers for your perusal including interesting publications from the emerging regions and recent papers on CML and COVID-19.

Read Professor Hughes' CML publications of the month: December 2021

Clinical papers

• TKI discontinuation in CML: how do we make more patients eligible?
  How do we increase the chances of a successful treatment-free remission?
  Hochhaus A and Ernst T. Hematology Am Soc Hematol Educ Program, December 2021
  - open access publication
• Lifelong TKI therapy: how to manage cardiovascular and other risks
  Mauro MJ. Hematology Am Soc Hematol Educ Program, December 2021
  – open access publication
• Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-crisis chronic myeloid leukemia (MATCHPOINT): a single-arm, multicentre phase 1/2 trial
  Copland M et al. Lancet Haematology, December 2021 (epub ahead of print)
• Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients
  Breccia M et al. Expert Rev Hematol, December 2021 (epub ahead of print)
• Low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial
  Murai K et al. Lancet Haematol, December 2021
• Low-dose dasatinib: when less can be more
  Amrein PC. Lancet Haematol, December 2021
• Blast and accelerated phase CML: room for improvement
  How J et al. Hematology Am Soc Educ Program, December 2021 - open access publication
  
• Matchpoint: the game is not over for blast-phase chronic myeloid leukemia
  Rousselot P. Lancet Hematol, December 2021 (epub ahead of print)
• Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation – First case series from a single institution
  Young PE et al. Leuk Res, December 2021

Scientific papers

• Shedding light on targeting chronic myeloid leukemia stem cells
  Houshmand M et al. J Clin Med, December 2021 – open access publication
• Antimetabolic cooperativity with the clinically approved L-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells
  Trinh A et al. Mol Metab, December 2021 – open access publication
• Description of PTPRG genetic variants identified in a cohort of chronic myeloid leukemia patients and their ability to influence response to tyrosine kinase inhibitors
  Ismail MA et al. Gene, December 2021 (epub ahead of print) - open access publication
• Quantitative proteomic analysis of plasma exosomes to identify the candidate biomarker of imatinib resistance in chronic myeloid leukemia patients
  Li MY et al. Front Oncol, December 2021 – open access publication
• Large-scale topological disruption of chromosome territories 9 and 22 is associated with nonresponse to treatment in CML
  Fabian-Morales E et al. Int J Cancer, December 2021 (epub ahead of print) – open access publication
• Screening and identification of key genes in imatinib-resistant chronic myelogenous leukemia cells: a bioinformatics study
  Zhang H et al. Hematology, December 2021 – open access publication
• Neutrophil extracellular traps are increased in chronic myeloid leukemia and are differently affected by tyrosine kinase inhibitors
  Telerman A et al. Cancers(Basel), December 2021 – open access publication

ERSAP papers

• Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel
  Pavlovsky C et al. Blood Adv, December 2021 – open access publication

Pediatric papers

• Comparison of the transcriptomic signature in pediatric and adult CML
  Youn M et al. Cancers(Basel), December 2021 – open access publication
• Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML
  Smith SM et al. Pediatr Hematol Oncol, December 2021 (epub ahead of print)

COVID-19 papers

COVID-19 and CML

• Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic leukemia patients on tyrosine kinase inhibitors
  Claudiani S et al. Br J Haematol, December 2021 (epub ahead of print) – open access publication
• Safety of SARS-CoV-2 vaccines in patients with chronic myeloid leukemia: a multicentre survey in China
  Yang et al. Clin Med J (Engl), December 2021 (epub ahead of print) – open access publication

COVID-19 and haematological malignancies

• Serum antibody response in patients with Philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines
  Kozak KE et al. Leukemia, December 2021 – open access publication